Aurora, Colorado – University of Colorado Cancer Center member Sana Karam, MD, PhD, has received a translational research grant from the V Foundation for Cancer Research, co-founded by ESPN and legendary basketball coach Jim Valvano, to study a new therapeutic that may help pancreatic cancer patients overcome resistance to radiation therapy. “Pancreatic cancer is deadly....
Latest News
Tallinn, Estonia – The chikungunya virus is widespread in tropical regions, where it is spread to humans by mosquitoes of the genus Aedes. Chikungunya is characterised by high fever, headache, muscle and joint pain, rash and sometimes diarrhoea. This viral disease has become a global health threat. At least five...
HOUSTON, TX ― A vaccine showed potential to prevent relapse of KRAS-mutated pancreatic and colorectal cancers for patients who had previously undergone surgery, according to a Phase I trial led by researchers at The University of Texas MD Anderson Cancer Center. Results were published today in Nature Medicine. In the...
This disease of colder months in temperate areas is practically non-existent in the U.S. due to an aggressive vaccination program for the past several decades. We currently see less than 5 cases of respiratory diphtheria annually. This dangerous respiratory disease is caused by a potent toxin produced by certain strains...
New York, NY – A new vaccine shows encouraging early results as a potential off-the-shelf treatment for certain patients with pancreatic or colorectal cancer, according to a study co-led by researchers at Memorial Sloan Kettering Cancer Center (MSK). The vaccine targets tumors with mutations (or changes) in the KRAS gene, a driving...
TOKYO & MUNICH & BASKING RIDGE, N.J. – New data from Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) for valemetostat, a potential first-in-class specific and potent dual inhibitor of EZH1 and EZH2, showed promising and durable tumor response in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) and adult T-cell leukemia/lymphoma...
A Valley boy diagnosed with a rare and fatal childhood disease is now being allowed access to an experimental drug. Denise and Rickey Miller’s 21-month-old son Woodrow has Niemann-Pick Disease Type C. It’s a form of childhood Alzheimer’s that eventually takes away the child’s ability to walk, talk, swallow, and breathe. For...
Saint-Herblain, France – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive final antibody persistence and safety data for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine, IXCHIQ®, in 304 children, twelve months after vaccination....
GRAND RAPIDS, Mich. (April 16, 2024) — A new study from Van Andel Institute scientists offers a first look into the complex molecular changes that occur in brain cells with Lewy bodies, which are key pathological hallmarks of Parkinson’s disease and some dementias. The findings, published in the journal Nature Communications, reveal...
WASHINGTON, DC — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for imsidolimab, a novel IgG4 IL-36 receptor antagonist, to treat generalized pustular psoriasis (GPP). Imsidolimab inhibits IL-36 receptor signaling, addressing the deficiency in the endogenous IL-36RA...